Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
89 Results for "
HER2 protein
" in MedChemExpress (MCE) Product Catalog:
Products (89)
89 Results for "HER2 protein" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-P73094
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ERBB2; P185erbB2; Prev. NGL; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (Neuro/Glioblastoma Derived Oncogene Homolog); HER2; V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog; NEU; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2 Isoform C; Receptor Tyrosine-protein Kinase ErbB-2; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncoprotein 2; Proto-Oncogene C-ErbB-2; Neuroblastoma/Glioblastoma Derived Oncogene Homolog; Proto-Oncogene Neu; Receptor Tyrosine-protein Kinase ErbB-2 Variant; P185(ErbB2); Truncated HER2 Splice Variant P100; C-ERB-2; Receptor protein-Tyrosine Kinase; C-ERB2; Metastatic Lymph Node Gene 19; MLN-19; Alternative protein ERBB2; HER-2; C-Erb B2/Neu protein; CD340; CD340 Antigen; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; HER-2/Neu; Tyrosine Kinase-Type Cell Surface Receptor HER2; HERstatin; Neuro/Glioblastoma Derived Oncogene Homolog; VSCN2; Human Epidermal Growth Factor Receptor 2; MLN19; Metastatic Lymph Node Gene 19 protein; TKR1; Erb-B2 Receptor Tyrosine Kinase 2; MLN 19
Species:
Human
Source:
HEK293
1
1 Cited Publications
Target:
Research Areas:
DOTA-NHS-ester is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer .
1
1 Cited Publications
STX-721 is an orally active, irreversible, covalent EGFR exon 20 insertion (ex20ins) inhibitor that selectively targets ex20ins-mutant dynamic protein states. STX-721 potently inhibits the kinase activity of EGFR ex20ins mutants (NPG, ASV, SVD). STX-721 inhibits phosphorylation of EGFR (pEGFR Y1068) and downstream ERK (pERK Thr202/Tyr204), and suppresses proliferation of ex20ins-mutant Ba/F3 cells and human NSCLC cell lines (NCI-H2073 ASV KI, CUTO-14 ASV). STX-721 induces tumor regression in EGFR ex20ins-mutant PDX/CDX models. STX-721 can be used for the study of non-small cell lung cancer (NSCLC) harboring EGFR or HER2 ex20ins mutations .
1
1 Cited Publications
Cat. No.: HY-128890B
Purity: 95.00%
Target:
Research Areas:
DOTA-NHS-ester TFA is a bifunctional reagent containing a DOTA chelating group and an NHS ester. DOTA-NHS-ester TFA can be conjugated to proteins/antibodies/HSA via primary amino groups for radiolabeling with radiometals, and when combined with 16-amino-1-hexadecanethiol hydrochloride, it enables the construction of self-assembled monolayers on gold surfaces for lectin microarrays. DOTA-NHS-ester TFA can be used to prepare DOTA-HSA-Z (HER2:342) imaging probes, as well as to construct Trop2-targeted radiotherapeutic and diagnostic probes for pancreatic cancer .
1
Target:
Research Areas:
ZEN-3694 (BET-IN-19) is an orally active BET inhibitor. ZEN-3694 regulates the function of BET proteins, thereby downregulating pathways involved in cell cycle regulation, ER signaling, AR signaling, AR splice variants, MYC, GR, cell growth, inflammation, and cellular immune responses. ZEN-3694 inhibits proliferation, induces apoptosis, reverses the upregulation of CDK6 and CCND1, restores cell cycle arrest, and inhibits CDK6 via miR-34a-5p. ZEN-3694 can be used in research related to HER2 breast cancer and metastatic castration-resistant prostate cancer .
1
1 Cited Publications
Cat. No.: HY-P80658
Synonyms: ERBB2; HER2; MLN19; NEU; NGL; Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD antigen CD340
Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models .
Cat. No.: HY-P99618
CAS No.: 2377419-89-9
Synonyms: IBI-315; BH2950
Target:
Research Areas:
Cat. No.: HY-N9330
CAS No.: 162558-94-3
Cat. No.: HY-176811
CAS No.: 3055318-88-9
VVD-442 is an inhibitor targeting PI3Kα. VVD-442 covalently binds to Cys242 in the RAS-binding domain of PI3K p110α, induces conformational changes, and disrupts the interaction between PI3K p110α and RAS proteins. VVD-442 also blocks RAS-mediated PI3K activation. VVD-442 can be used in research related to RAS-mutant cancers and HER2-overexpressing cancers .
Cat. No.: HY-161781
CAS No.: 3034605-72-3
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis, and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab (HY-P9907). HVH-2930 is applicable to relevant research on breast cancer .
Cat. No.: HY-21291
CAS No.: 186611-55-2
SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC50s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation .
Cat. No.: HY-E70715
The erbB family comprises 4 structurally related receptors: ErbB1 (EGFR), ErbB2 (HER2-neu), ErbB3 and ErbB4. On ligand stimulation, the receptor forms either homodimers or heterodimers, which activate their cytoplasmic domain. ERBB2 775YVMA776 Recombinant Human Active Protein Kinase is a recombinant ERBB2 775YVMA776 protein that can be used to study ERBB2 775YVMA776-related functions .
Cat. No.: HY-162589
Lw13 is a Hsp90 PROTAC degrader. Lw13 induces Hsp90 degradation via the ubiquitin-proteasome system, destabilizes client proteins HER2 and AKT, and blocks the activation of the HER2/AKT/mTOR signaling pathway. Lw13 inhibits the metastasis of cervical cancer cells, induces cell cycle arrest and apoptosis (apoptosis). Lw13 exerts synergistic anti-tumor activity with Cisplatin (HY-17394). Lw13 is applicable to cervical cancer-related research .
Cat. No.: HY-201330
CAS No.: 2531743-46-9
Synonyms: RGT-419B
GDC-4198 (RGT-419B) is an orally active CDK4/2 inhibitor with desired degrees of selectivity against kinases such as CDK6, CDK9 and GSK3β. GDC-4198 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. GDC-4198 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer .
Cat. No.: HY-164399
CAS No.: 1799802-29-1
SST0116CL1 is a HSP90 inhibitor (IC50: 0.21 μM). SST0116CL1 binds to the ATP binding pocket of Hsp90, and interferes with Hsp90 chaperone function thus resulting in client protein (EGFR, CDK4 and AKT) degradation. SST0116CL1 induces degradation of Her2 in BT-474 cell (IC50: 0.2 μM). SST0116CL1 has antiproliferative activity and inhibits tumor growth. SST0116CL1 can be used for the study of leukemia, gastric and ovarian carcinoma .
Cat. No.: HY-P991234
Cat. No.: HY-164487
CAS No.: 2401867-58-9
Target:
Research Areas:
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .
Cat. No.: HY-121881
CAS No.: 352519-21-2
PU3 is an Hsp90 inhibitor that competes with geldanamycin (GM) and others for the conserved ATP/ADP pocket of Hsp90. PU3 also induces degradation of proteins such as Her2 and inhibits breast cancer cell growth by causing retinoblastoma protein hypophosphorylation, G1 arrest, and cell differentiation. PU3 has the potential to be a cancer inhibitor. .
Cat. No.: HY-W738256
CAS No.: 180152-82-3
Synonyms: MDTPA
Research Areas:
Maleimide-DTPA (MDTPA) is a maleimide-functionalized bifunctional chelator that enables site-specific conjugation via a thioether bond to single-domain antibody fragments (sdAb) containing free cysteine, and mediates 111In radiolabeling. DTPA-2Rs15d-HLC, formed by the conjugation of Maleimide-DTPA with anti-HER2 sdAb 2Rs15d-HLC, retains high affinity for HER2 with a Kd of 5.9 nM, and maintains targeting ability to HER2-positive cells and tumors after 111In labeling. Maleimide-DTPA can be used for radiotracer construction, SPECT molecular imaging, and HER2-positive tumor research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
